Loading headlines…

Collected headline brief
British pharmaceutical giant GSK has agreed to acquire a cancer drug from Chinese firm Chimagen Biosciences in a deal worth up to US$750 million, underscoring China’s emergence as a global player in biotechnology. GSK announced plans on…
Complete reading on newsGlobal
Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →Full article · 4 min read
AI-generated editorial illustration / newsGlobal. Not a photograph of an actual event.
Read the full article →There is more to this story